<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="preprint">
<?all-math-mml yes?>
<?use-mml?>
<?origin ukpmcpa?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">bioRxiv</journal-id>
<journal-title-group>
<journal-title>bioRxiv : the preprint server for biology</journal-title>
</journal-title-group>
<issn pub-type="ppub"/>
</journal-meta>
<article-meta>
<article-id pub-id-type="manuscript">EMS98566</article-id>
<article-id pub-id-type="doi">10.1101/2020.10.14.339689</article-id>
<article-id pub-id-type="archive">PPR226110</article-id>
<article-version article-version-type="publisher-id">1</article-version>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>COVID19: Exploring uncommon epitopes for a stable immune response through MHC1 binding</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Abitogun</surname>
<given-names>Folagbade</given-names>
</name>
<aff id="A1">University College Hospital, Ibadan, Nigeria</aff>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Srivastava</surname>
<given-names>R.</given-names>
</name>
<aff id="A2">Biological Life Science Division, Ahmedabad University, Gujarat, India</aff>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sharma</surname>
<given-names>S.</given-names>
</name>
<aff id="A3">Department of Biochemistry, Deshbandhu College, University of Delhi, New Delhi, India</aff>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Komarysta</surname>
<given-names>V.</given-names>
</name>
<aff id="A4">Department of Botany and Plant Ecology, V.N Karazin Kharkiv National University, Kharkiv, Ukraine</aff>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Akurut</surname>
<given-names>E.</given-names>
</name>
<aff id="A5">Department of Immunology and Molecular Biology, College of Health Sciences, Makerere University, Uganda</aff>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Munir</surname>
<given-names>N.</given-names>
</name>
<aff id="A6">Faculty of Pharmacy and Biotechnology, German University in Cairo (GUC), Cairo, Egypt</aff>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Macalalad</surname>
<given-names>L.</given-names>
</name>
<aff id="A7">Department of Biology, College of Science, Pamantasan ng Lungsod ng Maynila (PLM), Manila, Philippines</aff>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Olawale</surname>
<given-names>O.</given-names>
</name>
<aff id="A8">Department of Medical Microbiology, State Specialist Hosipital, Akure, Ondo State, Nigeria</aff>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Owolabi</surname>
<given-names>O.</given-names>
</name>
<aff id="A9">Future Health Systems, Faculty of Public Health, University of Ibadan, Oyo State, Nigeria</aff>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Abayomi</surname>
<given-names>G.</given-names>
</name>
<aff id="A10">Department of Physiology, Babcock University, Ogun State, Nigeria</aff>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Debnath</surname>
<given-names>S.</given-names>
</name>
<aff id="A11">Department of Medical Laboratory Technology, Women Polytechnic, Tripura, India</aff>
</contrib>
</contrib-group>
<pub-date pub-type="nihms-submitted">
<day>16</day>
<month>10</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="preprint">
<day>14</day>
<month>10</month>
<year>2020</year>
</pub-date>
<permissions>
<license license-type="open-access" xlink:href="https://europepmc.org/downloads/openaccess">
<license-p>This preprint is made available via the <ext-link ext-link-type="uri" xlink:href="https://europepmc.org/downloads/openaccess">Europe PMC open access subset</ext-link>, for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original preprint source.</license-p>
</license>
</permissions>
<abstract>
<p id="P1">The COVID19 pandemic has resulted in 1,092,342 deaths as of 14<sup>th</sup> October 2020, indicating the urgent need for a vaccine. This study highlights novel protein sequences generated by shot gun sequencing protocols that could serve as potential antigens in the development of novel subunit vaccines and through a stringent inclusion criterion, we characterized these protein sequences and predicted their 3D structures. We found distinctly antigenic sequences from the SARS-CoV-2 that have led to identification of 4 proteins that demonstrate an advantageous binding with Human leukocyte antigen-1 molecules. Results show how previously unexplored proteins may serve as better candidates for subunit vaccine development due to their high stability and immunogenicity, reinforce by their HLA-1 binding propensities and low global binding energies. This study thus takes a unique approach towards furthering the development of vaccines by employing multiple consensus strategies involved in immuno-informatics technique.</p>
</abstract>
<kwd-group>
<kwd>Covid-19</kwd>
<kwd>SARS CoV-2</kwd>
<kwd>HLA-1 Binding Propensities</kwd>
<kwd>Structure Predictions</kwd>
<kwd>Stability analysis</kwd>
<kwd>Epitope predictions</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="S1" sec-type="intro">
<title>Introduction</title>
<p id="P2">Coronaviruses are a large group of viruses that are rather common throughout the community, causing illness ranging from the common cold to more severe diseases such as Severe Acute Respiratory Syndrome (SARS-CoV) and Middle East Respiratory Syndrome (MERS-CoV) (<xref ref-type="bibr" rid="R1">1</xref>). The previous outbreaks of these coronaviruses in 2003 and 2015 respectively show similarities to the novel coronavirus (<xref ref-type="bibr" rid="R2">2</xref>), which was first reported in December 2019 in Wuhan (<xref ref-type="bibr" rid="R3">3</xref>). It was later declared as a pandemic on 11th March, 2020 by the World Health Organization (WHO) having caused a global emergency across many countries and territories around the world.</p>
<p id="P3">The causative agent of the COVID-19 disease is the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which was initially tagged as 2019 novel coronavirus (2019-nCoV) by the World Health Organization (<xref ref-type="bibr" rid="R4">4</xref>) before genomic studies revealed a 79.5% and 96% nucleotide level similarity with SARS-CoV and bat coronavirus respectively (<xref ref-type="bibr" rid="R5">5</xref>,<xref ref-type="bibr" rid="R6">6</xref>), hence necessitating its new identity. Further analysis on its similarity with SARS-CoV and MERS-CoV including phylogeny revealed that it is categorized under the family Coronaviridae, order Nidoviralae and genus Betacoronavirus alongside the other two viruses which have also caused pandemic situations in the past, causing thousands of death globally. (<xref ref-type="bibr" rid="R7">7</xref>,<xref ref-type="bibr" rid="R8">8</xref>)</p>
<p id="P4">The structural architecture of SARS-CoV-2 is an elaborate one, containing a positive single stranded RNA as its genetic element with genomic length of about 29-30 kilobases, (<xref ref-type="bibr" rid="R9">9</xref>) which encodes the major structural proteins being the spike (S) glycoprotein, membrane (M) protein, envelope (E) protein, and nucleocapsid (N) protein. (<xref ref-type="bibr" rid="R10">10</xref>,<xref ref-type="bibr" rid="R11">11</xref>) The structure of the spike glycoprotein of the virus is also an extended similarity with SARS-CoV, (<xref ref-type="bibr" rid="R4">4</xref>) which together with COVID19: Exploring uncommon epitopes for a stable immune response through MHC1 binding other proteins of the virus are candidates for vaccine development and are being explored in different settings due to the active roles of the proteins in the infectivity of the virus. (<xref ref-type="bibr" rid="R12">12</xref>–<xref ref-type="bibr" rid="R15">15</xref>) Developing an effective treatment for SARS-CoV-2 is a research priority. Currently, different therapeutic strategies are being utilized by researchers to combat this dangerous COVID-19, with much of the focus being on developing novel drugs or vaccines. However, in recent years, the development of vaccine design has been revolutionized by the reverse vaccinology (RV), which aims to first identify promising vaccine candidate through bioinformatics analysis of the pathogen genome. One of the successes of this method is the Bexsero vaccine, discovered for Group B meningococcus. (<xref ref-type="bibr" rid="R16">16</xref>) This immuno-informatics method includes the identification of peptide epitopes in the virus genome which can then be prepared by chemical synthesis techniques. These epitopes are easier in quality control; however, there is the need for structural modifications as well as the inclusion of delivery systems, and adjuvants in their formulation due to the low immunogenicity of the epitopes which is a result of their structural complexity and low molecular weight. (<xref ref-type="bibr" rid="R17">17</xref>)</p>
<p id="P5">Recently, a set of B and T cell epitopes highly conserved in SARS-CoV-2 were identified from the S and N proteins of SARS-CoV. (<xref ref-type="bibr" rid="R18">18</xref>) However studies have shown that full length spike protein vaccines for SARS-CoV may lead to antibody mediated disease enhancement causing inflammatory and liver damage in animal models (<xref ref-type="bibr" rid="R19">19</xref>,<xref ref-type="bibr" rid="R20">20</xref>) which is why in this manuscript, we applied immuno-informatics “in silico” approaches to identify potential CD8+ cytotoxic T Cell epitopes from proteins of SARS-CoV-2, SARS-CoV and MERS-CoV. In achieving this, the ~29.8kb genome of the SARS-CoV-2 which encodes for 28 proteins comprising 5 structural proteins, 8 accessory proteins and 15 non-structural proteins as well as the ~30kb genome of SARS-CoV-1 comprising 14 open reading frames (ORF) were explored for some uncommon proteins of the viruses with therapeutic potentials. Identified proteins were thus considered for highly antigenic epitope prediction and evaluation. The antigenicity and immunogenicity of all identified epitopes was estimated and their interactions with the human leukocyte antigen (HLA) class I system were evaluated, owing to the wide usage of the HLA system as a strategy in the search for the etiology of infectious diseases and autoimmune disorders, (<xref ref-type="bibr" rid="R21">21</xref>) as was explored in the case of SARS-CoV-1 after the first epidemic that broke out in East Asia in 2002-2003. This is linked to the fact that HLA genes are known to display the highest level of diversity in the genome, with thousands of different alleles now reported. Each of these alleles is also a combination of multiple single nucleotide polymorphisms (SNPs). This, we also investigated the HLA-class I system for evidence of disease association, with the hope that the discovery of disease susceptibility will help in developing protection such as vaccines against the virus.</p>
</sec>
<sec id="S2" sec-type="methods">
<title>Methods</title>
<sec id="S3">
<title>Protein sequence retrieval</title>
<p id="P6">The UniProt (<xref ref-type="bibr" rid="R22">22</xref>) database was searched for the protein sequences inferred from the genome sequence analysis of different isolates of highly pathogenic human coronaviruses. The SARS CoV, MERS-CoV, and SARS-CoV-2 proteins without experimentally defined 3D structure or functional annotation were chosen for further analysis and their sequence files in the FASTA format were downloaded.</p>
</sec>
<sec id="S4">
<title>Sequence analysis and physicochemical parameters evaluation</title>
<p id="P7">The FASTA sequences were used to infer the physicochemical properties of the chosen uncharacterized viral proteins. With tools and servers including ExPASyProtParam, (<xref ref-type="bibr" rid="R23">23</xref>) EMBOSS Pepstats (<xref ref-type="bibr" rid="R24">24</xref>), Peptide 2.0, (<xref ref-type="bibr" rid="R25">25</xref>) PROTEIN CALCULATOR v3.4, (<xref ref-type="bibr" rid="R26">26</xref>) important physicochemical properties of the proteins including the sequence length and molecular weight, theoretical isoelectric point (IpH), hydrophobicity/hydrophilicity and polarity indices (calculated as the percentage of hydrophobic, hydrophilic and polar amino acids respectively), the content of the basic amino acids (arginine, histidine, lysine), and disulfide bond allowing cysteine were evaluated and computed. No less than three online tools were used to calculate each parameter; the consensus results were chosen for presentation in this paper.</p>
</sec>
<sec id="S5">
<title>Tertiary structure modeling</title>
<p id="P8">The 3D structures of the retrieved viral proteins were obtained using different homology modeling tools of which at least four are approved by CASP. (<xref ref-type="bibr" rid="R27">27</xref>) Homology 3D protein modeling against the protein templates with experimentally defined tertiary structure was done using the following online servers: SWISS-MODEL, (<xref ref-type="bibr" rid="R28">28</xref>) LOMETS, (<xref ref-type="bibr" rid="R29">29</xref>) IntFold, (<xref ref-type="bibr" rid="R30">30</xref>) I-TASSER, (<xref ref-type="bibr" rid="R31">31</xref>) FALCON, (<xref ref-type="bibr" rid="R32">32</xref>) GalaxyWeb. (<xref ref-type="bibr" rid="R33">33</xref>) The other tools used utilize different approaches: RaptorX (<xref ref-type="bibr" rid="R34">34</xref>) exploits distance-based protein folding powered by deep learning; QUARK (<xref ref-type="bibr" rid="R35">35</xref>) implements ab initio protein folding based on building from small fragments by replica-exchange Monte Carlo simulation under the guide of an atomic-level knowledge-based force field. Application of different algorithms lying behind each modeling tool provided various variants of 3D structure models for each protein. Up to five top models of each protein resulting from every tool were selected for further processing.</p>
</sec>
<sec id="S6">
<title>Refinement and validation of tertiary structure</title>
<p id="P9">Each model was refined using a molecular dynamics simulation approach implemented by GALAXY Refine (<xref ref-type="bibr" rid="R36">36</xref>) tool or rapid energy minimization using discrete molecular dynamics with an all-atom representation for each residue implemented by Chiron server. (<xref ref-type="bibr" rid="R37">37</xref>) The top refined model was chosen for every protein based on the refinement servers output model quality indices. The further Ramachandran analysis with PROCHECK (<xref ref-type="bibr" rid="R38">38</xref>) and Saves v5.0 tools Verify3D, (<xref ref-type="bibr" rid="R39">39</xref>) ERRAT, (<xref ref-type="bibr" rid="R40">40</xref>) and PROVE (<xref ref-type="bibr" rid="R41">41</xref>) was performed on the top models of all proteins initially included in the analysis. Thermodynamic stability of the molecules was predicted using SCooP analysis. (<xref ref-type="bibr" rid="R42">42</xref>) GROMOS96 (<xref ref-type="bibr" rid="R43">43</xref>) force field calculations were applied to identify the most stable protein structures. Eight (<xref ref-type="bibr" rid="R8">8</xref>) protein models with the most geometrically and thermodynamically stable structures that most likely represent the native 3D structures of coronavirus proteins were finally selected.</p>
</sec>
<sec id="S7">
<title>Antigenicity prediction</title>
<p id="P10">Antigenicity prediction of the top eight uncharacterized coronavirus proteins selected after 3D molecular models’ validation was performed using VaxiJen tool. (<xref ref-type="bibr" rid="R44">44</xref>) A threshold value of 0.4 was taken into account. Non-antigenic peptides having VaxiJen scores less than 0.4 were discarded, while antigenic epitopes with scores higher than 0.4 were further prioritized for their immunogenicity. The proteins predicted to be non-antigens were discarded from the further analysis.</p>
</sec>
<sec id="S8">
<title>T Cell Epitope Prediction and binding MHC class I alleles</title>
<p id="P11">Antiviral immunity relies on the ability of major histocompatibility complex (MHC) class I molecules to bind antigen molecules and display them to T cells. In humans, MHC class I is represented by human leukocyte antigens HLA-A, HLA-B, and HLA-C that are very polymorphic among human populations. The most common for African and Asian populations HLA-A, HLA-B, and HLA-C subtypes were retrieved from Allele Frequency Net Database. (<xref ref-type="bibr" rid="R45">45</xref>) NetMHCpan 4.1 server (<xref ref-type="bibr" rid="R46">46</xref>) which applies artificial neural networks (ANNs) trained on a combination of more than 850,000 quantitative Binding Affinity (BA) and Mass-Spectrometry Eluted Ligands (EL) peptides to predict the binding of peptides to any MHC molecule of known sequence was used to predict strong binding epitope sequences from these top 10 models. The strong binding epitope sequences predicted from the NETMHCpan server were then analyzed for their antigenicity using Vaxijen (<xref ref-type="bibr" rid="R45">45</xref>) (threshold = 0.4). Further analysis including immunogenicity, allergenicity and toxicity of the peptide epitopes were done using IEDB Immunogenicity analysis resource (Class I Immunogenicity), (<xref ref-type="bibr" rid="R47">47</xref>) AllerTOP v. 2.0 (<xref ref-type="bibr" rid="R48">48</xref>) and ToxinPred (<xref ref-type="bibr" rid="R49">49</xref>) servers respectively. Peptide epitopes with the most immunogenic sequences which were non allergens and nontoxic were used for molecular docking simulations with specific HLA-1 alleles.</p>
</sec>
<sec id="S9">
<title>Molecular docking between MHC class I and predicted peptide epitopes 3D structures</title>
<p id="P12">The 3D structures for the most immunogenic sequences were generated using PEPFOLD3 server (<xref ref-type="bibr" rid="R50">50</xref>) which applies a de novo approach based on a new Hidden Markov Model sub-optimal conformation sampling to predict models for peptides from 5 to 50 amino acids. HLA structures based on the binding predictions from NETMHCpan were downloaded from RCSB PDB and isolated from their complexes using Chimera. (<xref ref-type="bibr" rid="R51">51</xref>) Molecular docking of these molecules was carried out by PatchDock (<xref ref-type="bibr" rid="R52">52</xref>) which employs a surface patch matching algorithm inspired by object recognition and image segmentation techniques to dock the molecules. The top 1000 results from PatchDock were then submitted to FireDock (<xref ref-type="bibr" rid="R53">53</xref>) for refinement of protein-protein docking solutions. Given a set of up to 1000 potential docking candidates, FireDock refines and scores them according to an energy function, spending about 3.5 seconds per candidate solution. Each candidate is subsequently refined by restricted interface side-chain rearrangement and by soft rigid-body optimization. The side-chain flexibility is modeled by rotamers and the obtained combinatorial optimization problem is solved by integer linear programming. Following rearrangement of the side-chains, the relative position of the docking partners is refined by Monte Carlo minimization of the binding score function. The refined candidates are ranked by the binding score which is a combination of Atomic Contact Energy, softened Van der Waals interactions, partial electrostatics and additional estimations of the binding free energy.</p>
</sec>
<sec id="S10">
<title>Conservancy Analysis</title>
<p id="P13">In order to identify functionally important regions in the selected proteins and the selection of epitopes with the desired degree of conservation, Consurf (<xref ref-type="bibr" rid="R54">54</xref>) was used to determine the variability of epitopes within the selected proteins. The degree of conservation at each amino acid site is similar to the inverse of the site's rate of evolution; slowly evolving sites are evolutionarily conserved while fast evolving sites are variable. (<xref ref-type="bibr" rid="R55">55</xref>) Amino acid residues that are crucial for retention of protein function are believed to be associatedwith inherently lower variability, even under immune pressure and as such often represent good targets for the development of epitope-based vaccines. (<xref ref-type="bibr" rid="R56">56</xref>) Both 3D structure and FASTA sequences of the proteins were used as inputs and the Consurf server carries out both a PSI-BLAST search for close homologues and a multiple sequence alignment using CLUSTAL W. The server thus builds a phylogenetic tree that is consistent with the MSA and then calculates the conservation grades which are color-coded, taking into account the evolutionary relationship between the homologues.</p>
</sec>
</sec>
<sec id="S11" sec-type="results">
<title>Results</title>
<sec id="S12">
<title>Human Coronavirus uncharacterized protein sequences analysis</title>
<p id="P14">A total of 8 non-structural sequences were identified and retrieved from UniProtKB database. The mass, isoelectric-pH, Basic amino acid %, Cysteine %, Polarity and Hydrophobicity of the protein sequences were computed and outlined in <xref ref-type="table" rid="T1">table 1</xref>. The lengths of these protein sequences varied from 39 to 275 amino acid residues. Cysteine was found to have the highest presence in the selected proteins with an average of 5.56% and its highest presence was observed in proteinQ7TFA0 with 15.40%. Arginine, Lysine and Histidine have an average presence of 2.35%, 3.69% and 4.36% respectively. The polarity and non polarity of the final selected proteins ranged from 27.907%to 63.839 % and from 36.161%to 72.093% respectively with M4SVF1 having the highest percentage of polar amino acids (63.839%) while P0DTD8 has the highest percentage of non-polar amino acids (72.093%). Likewise, the highest hydrophobicity index was recorded for P0DTD8.</p>
</sec>
<sec id="S13">
<title>Protein 3D Structure Predictions</title>
<p id="P15">After obtaining the 3D structures of the proteins from modeling servers, the models were refined using GalaxyRefine. Upon refinement, the models were subjected to stereochemical and thermodynamic stability analysis. Particularly, the models with highest Ramachandran favored residues and lowest clash scores were used for energy analysis using Chiron, SCooP and ERRAT servers as highlighted in <xref ref-type="table" rid="T2">table 2</xref>. All the protein structures had a Ramachandran score of over 89% and an ERRAT value of over 60, with Q7TFA0, P0DTD8 and P0DTD3 all having a perfect 100% Ramachandran scores. The free energy of the structures ranged from -28.7kcal/mol (Q7TFA0) to -2.2 kcal/mol (A0A6H2LBE3). Force field values ranging from - 5955.989 (A0A6H2LBE3) to -435.783 (P0DTD8) were observed using GROMOS96 implementation of the Swiss-PDB Viewer. The models with lowest overall energies were determined to be stable.</p>
</sec>
<sec id="S14">
<title>Viral Protein Antigenicity Predictions</title>
<p id="P16">VaxiJen Antigenicity prediction was used to predict the overall antigenicity of the 8 proteins as outlined in <xref ref-type="table" rid="T3">table 3</xref>. Two proteins: M4SVF1_MERS and Q7TFA0 were predicted to be non-antigens with their antigenicity scores of 0.3373 and 0.1251 respectively while P0DTD8 and P0DTC8 showed very high antigenicity owing to their high scores of 0.8462 and 0.6502 respectively.</p>
</sec>
<sec id="S15">
<title>Human Leukocyte Antigen Interactions</title>
<p id="P17">T-cell epitope prediction was carried out using IEDB, EpiJen, PepVac, Rankpep, and NetMHC. Initially, 15,181 HLA class I binding epitopes were predicted from 6 out of 8 stable proteins which were predicted to be antigenic. Scrutiny on the basis of percentile rank filtered 112 peptide epitopes. Considerable binding affinity for 5 HLA-1 subtypes with high frequencies in Asia and Africa (HLA-A*02:01, HLA-A*11:01, HLA-B*08:01, HLA-B*27:05 and HLA B*58:01) was observed from NETMHCpan server which predicted high affinity binders (&lt;0.5 percentile rank) using EL-Ranks. Among predicted epitopes of SARS-CoV-2 virus, ten (<xref ref-type="bibr" rid="R10">10</xref>) epitopes showed considerably high immunogenicity towards the MHC-Class 1 molecules which were then selected for further analysis (<xref ref-type="table" rid="T4">Table 4</xref>). All the predicted epitopes were further subjected to allergenic and toxicity analysis, with all 10 coming out as non-allergens and non toxins (<xref ref-type="table" rid="T4">Table 4</xref>). Epitopes including HLVDFQVTI, RKSAPLIEL, and YLCFLAFLL showed remarkably high antigenic tendencies, scoring 1.4119, 1.1591 and 0.9143 respectively. All of these epitopes, along with their features are reported in <xref ref-type="table" rid="T4">Table 4</xref>. The structures of HLA-1 Subtypes namely, HLA-A*02:01, HLA-A*11:01, HLA-B*08:01, HLA-B*27:05 and HLA-B*58:01 were obtained from RCSB PDB (<xref ref-type="table" rid="T5">Table 5</xref>). Further docking analysis resulted in a total of 10 global binding energies predictions which were refined with FireDock (Table 6). The global binding energies range from -68.71 to -11.19 indicating that all the proposed epitope sites from the modelled proteins can serve as good antigens.</p>
</sec>
<sec id="S16">
<title>Conservation Analysis of the Selected T-cell epitopes</title>
<p id="P18">The conservation status of each residue in the selected T-cell epitopes in four (<xref ref-type="bibr" rid="R4">4</xref>) SARS COV-2 proteins (Q7TLC7, P0DTC6, P0DTD8, P0DTC8) were examined using ConSurf. Results revealed that the highly conserved and exposed residues are found in all 4 proteins, with P0TDC6 and P0DTC8 having the larger amount of these residues. Particularly, the epitopes without allergenicity and toxicity containing at least one predicted functional residue (highly conserved and exposed) included epitopes ‘RKSAPLIEL’ and ‘HLVDFQVTI’ while T-cell epitopes ‘RKSAPLIEL', ‘FLAFLLFLV’, and ‘HLVDFQVTI’ contained at least one predicted structural residue (highly conserved and buried). Interestingly, none of the epitopes from P0DTD8 contained any functional residues (highly conserved and exposed) while the highest concentration of predicted structural and functional residues was found in two epitopes HLVDFQVTI (1 functional residue and 3 structural residues) and RKSAPLIEL (3 functional residues and 1 structural residue)- from the protein P0DTC6.</p>
</sec>
</sec>
<sec id="S17" sec-type="discussion">
<title>Discussion</title>
<p id="P19">Despite the continuous unrest caused by the COVID19 pandemic, considering the 1,886,643 new cases recorded as of 7th September, 2020 which has spiked up the total reported cases to over 26.7 million and a total of 876,616 deaths globally, there is currently no available FDA-approved vaccine against COVID-19 (<xref ref-type="bibr" rid="R57">57</xref>). If a vaccine is successfully developed against COVID-19, this will improve global human health. Advancement in Technology has led to various Bioinformatic approaches such as Reverse Vaccinonology (RV) and immune-informatics being applied to revolutionize vaccine production in terms of production cost and time which has been a major setback in vaccine development. Antibody response as well as cell mediated immunity can be established by using proper protein antigen. Reverse vaccinology (RV) has been useful in identification of potential vaccine candidates against pathogens and the world is in a race to get one against SARS-COV2. This approach presents an advantage over other vaccine approaches because it can identify all potential antigens coded by a genome irrespective of their abundance, phase of expression and Immunogenecity.</p>
<p id="P20">While most of the previous protein vaccines against SARS-CoV have focused on the full length spike protein of the virus, the vaccine development race against the COVID19 virus have followed the same path, with a larger percentage of the 69 of the 210 vaccines currently in development utilizing the spike protein of the SARS-CoV-2 (<xref ref-type="bibr" rid="R58">58</xref>) not minding the reported negative side effects, including liver damage and antibody mediated inflammatory diseases, of the full length spike protein vaccines and other whole organism vaccines in the host. Additionally, while novel technologies and approaches such as Next-generation vaccines enabled through advances in nanotechnology which relies on the principle that nanoparticles and viruses operate at the same length scale are poised to make a clinical impact for the first time, many of these platforms may be several years away from deployment and therefore may not have an impact on the current SARS-CoV-2 pandemic, further necessitating the priority given to the quicker and safer vaccine development platforms. The current study focused on the HLA-1 binding propensities of some uncommon proteins from COVID-19 virus. Obtaining these antigenic epitopes using the immune-informatics approach will help inform which epitopes to use in the construct of protein vaccines against SARS-CoV-2 using proteins other than the spike protein. From the 8 selected proteins obtained all the models with good stability analysis including the Ramachandran analysis, which is a two dimensional plot drawn in the space of angles ϕ and ψ that quantify the rotation of the protein backbone and thus play a crucial role in the secondary structure of proteins and later the tertiary structure, were further analyzed for antigenicity and only highly antigenic proteins were selected for further analysis since the highly antigenic proteins will induce better immune response in the host.</p>
<p id="P21">Five (5) of the 35 most common HLA-1 subtypes in Africa and Asia that were identified in this study were included in the analyses and their potential interactions between identified epitopes from the proteins were predicted using the NetMHCpan 4.1 server. The binding affinities between these HLA subtypes and the epitopes were indicated by the server which allowed the selection of epitopes that will have strong interactions with the HLA alleles. The analysis of this interaction is important because vaccination is a proven strategy for protection from disease and an ideal vaccine would include antigens that elicit a safe and effective protective immune response. HLA-restricted epitope vaccines, including T-lymphocyte epitopes restricted by HLA alleles, embodies a newly developing and favorable immunization approach. Research in HLA restricted epitope vaccines to be used for the treatment of tumors as well as for the prevention of viral, bacterial, and parasitic infections have, in recent years, achieved substantial progress and this further strengthens the resolve of the HLA-binding propensities analysis done in this study. The predicted strongest binding epitopes were thus further subjected to immunogencity evaluation which checked the ability of the epitope to induce an immune response and also predicted how strongly they will induce an immune response; Allergenicity which verified the potential of our epitopes to cause sensitization or allergic reactions related to IgE antibody responses; and Toxicity which is its ability to cause bodily harm. Using these criteria, 10 epitopes were identified and these could be potential epitopes for vaccine constructs against SARS-CoV-2. This was also evinced by the lower global binding energies between our identified epitopes and the HLA molecules, ranging from -68.71 to -11.19, indicating stable complexes formed between them.</p>
</sec>
<sec id="S18" sec-type="conclusions">
<title>Conclusion</title>
<p id="P22">Our extensive approach towards the prediction of stable protein structures from previously uncharacterized proteins and the subsequent application of immune-informatics for the identification of immunogens has resulted in the classification of 10 different epitope sites from 8 different proteins that have high antigenicity and low binding energies with HLA-1 alleles that are most commonly present in the continent of Asia and Africa. These epitopes have high tendencies to provide effective and strong protective cytotoxic immunity against the SARS CoV-2 if they are adequately exploited for vaccine production. A multiple consensus approach ensures the reliability and reproducibility of these results. This study thus provides further knowledge on the association of these HLA-1 alleles with COVID19, suggesting that good peptide coverage can be achieved by many different combinations of HLA-1 alleles.</p>
</sec>
</body>
<back>
<ack id="S19">
<title>Acknowledgments</title>
<p>We acknowledge the support of DNACompass, CMESBAHF Nigeria, BIOTRUST Scientific, Galaxy Project and NeliRef for this project. We also acknowledge the provision of figure images generated by Rajavee Srivastava and Folagbade Abitogun from UCSF Chimera, Discovery Studio, PyMol, MHC Cluster Server v 2.0 and Consurf. We acknowledge T. Thao, H. Aminu, and V. Ekundayo for their contribution to this project.</p>
</ack>
<bio id="B1">
<p id="P23">
<bold>Author Bio</bold>
</p>
<p id="P24">Folagbade Abitogun is a Research Associate at the University College Hospital, Ibadan, Nigeria. He is currently actively involved in antimicrobial resistant research and he has deep interest in the interplay between the human immune system and the clearance of infectious diseases, using molecular and bioinformatics approaches.</p>
</bio>
<ref-list>
<ref id="R1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roy</surname>
<given-names>Arpita Singha</given-names>
</name>
<name>
<surname>Quadery Tommy</surname>
<given-names>Mahafujul Islam</given-names>
</name>
<name>
<surname>Fariha</surname>
<given-names>Atqiya</given-names>
</name>
<name>
<surname>Hami</surname>
<given-names>Ithmam</given-names>
</name>
<name>
<surname>Afif</surname>
<given-names>Ibrahim Khalil</given-names>
</name>
<name>
<surname>Adnan</surname>
<given-names>Md</given-names>
</name>
<etal/>
</person-group>
<article-title>Multi-epitope Based Peptide Vaccine Design Using Three Structural Proteins (S, E, and M) of SARS-CoV-2: An In Silico Approach</article-title>
<source>BioRxiv</source>
<year>2020</year>
<pub-id pub-id-type="doi">10.1101/2020.06.13.149880</pub-id>
</element-citation>
</ref>
<ref id="R2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giao</surname>
<given-names>Huynh</given-names>
</name>
<name>
<surname>Han Nguywen</surname>
<given-names>Thi Ngoc</given-names>
</name>
<name>
<surname>Tran</surname>
<given-names>Van Khanh</given-names>
</name>
<name>
<surname>Vo</surname>
<given-names>Kim Ngan</given-names>
</name>
<name>
<surname>Pham</surname>
<given-names>Van Tam Vo’ Le An</given-names>
</name>
</person-group>
<article-title>Knowledge and attitude toward COVID-19 among healthcare workers at District 2 Hospital, Ho Chi Minh City</article-title>
<source>Asian Pac J Trop Med</source>
<year>2020</year>
<volume>13</volume>
<fpage>260</fpage>
<comment>52020</comment>
</element-citation>
</ref>
<ref id="R3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saqlain</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Munir</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Rehman</surname>
<given-names>SU</given-names>
</name>
<name>
<surname>Gulzar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Naz</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ahmed</surname>
<given-names>Z</given-names>
</name>
<etal/>
</person-group>
<article-title>Knowledge, attitude, practice and perceived barriers among healthcare professionals regarding COVID-19: A Cross-sectional survey from Pakistan</article-title>
<source>J Hosp Infect</source>
<year>2020</year>
<volume>105</volume>
<issue>3</issue>
<fpage>419</fpage>
<lpage>423</lpage>
<pub-id pub-id-type="doi">10.1017/CBO9781107415324.004</pub-id>
</element-citation>
</ref>
<ref id="R4">
<label>4</label>
<element-citation publication-type="web">
<collab>World Health Organization</collab>
<article-title>Naming the coronavirus disease (COVID-19) and the virus that causes it</article-title>
<year>2020</year>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirusdisease-(covid-2019)-and-the-virus-that-causes-it">https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirusdisease-(covid-2019)-and-the-virus-that-causes-it</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Dingyu</surname>
<given-names>Zhang</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Wenling</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Xingwang</given-names>
</name>
<name>
<surname>Bo</surname>
<given-names>Yang</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>Jingdong</given-names>
</name>
<etal/>
</person-group>
<article-title>A novel coronavirus from patients with pneumonia in China 2019</article-title>
<source>N Engl J Med</source>
<year>2020</year>
<volume>382</volume>
<fpage>727</fpage>
<lpage>733</lpage>
</element-citation>
</ref>
<ref id="R6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Xing-Lou</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Xian-Guang</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Lei</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Wei</given-names>
</name>
<etal/>
</person-group>
<article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title>
<source>Nature</source>
<year>2020</year>
<volume>579</volume>
<fpage>270</fpage>
<lpage>273</lpage>
</element-citation>
</ref>
<ref id="R7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Badawi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ryoo</surname>
<given-names>SG</given-names>
</name>
</person-group>
<article-title>Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis</article-title>
<source>Int J Infect Dis</source>
<year>2016</year>
<volume>49</volume>
<fpage>129</fpage>
<lpage>133</lpage>
</element-citation>
</ref>
<ref id="R8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kirchdoerfer</surname>
<given-names>Hannah L</given-names>
</name>
<name>
<surname>Turneret</surname>
<given-names>al</given-names>
</name>
</person-group>
<article-title>Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen</article-title>
<source>Nat l Acad Sci</source>
<year>2017</year>
<volume>114</volume>
<issue>35</issue>
<pub-id pub-id-type="doi">10.1073/pnas.1707304114</pub-id>
</element-citation>
</ref>
<ref id="R9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Xiang</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Juan</given-names>
</name>
<name>
<surname>Niu</surname>
<given-names>Peihua</given-names>
</name>
<name>
<surname>Bo</surname>
<given-names>Yang</given-names>
</name>
<name>
<surname>Honglong Wuet</surname>
<given-names>al</given-names>
</name>
</person-group>
<article-title>Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding</article-title>
<source>Lancet</source>
<year>2020</year>
<volume>395</volume>
<issue>10224</issue>
<fpage>565</fpage>
<lpage>574</lpage>
</element-citation>
</ref>
<ref id="R10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Narayanan</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Maeda</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Maeda</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Makino</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Characterization of the Coronavirus M Protein and Nucleocapsid Interaction in Infected Cells</article-title>
<source>J Virol</source>
<year>2000</year>
<volume>74</volume>
<issue>17</issue>
<fpage>8127</fpage>
<lpage>8134</lpage>
</element-citation>
</ref>
<ref id="R11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>Yimei</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Chang</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Xing</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Xingguo</given-names>
</name>
<name>
<surname>Shuliang Zhouet</surname>
<given-names>al</given-names>
</name>
</person-group>
<article-title>Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan, China</article-title>
<source>Critical Care</source>
<year>2020</year>
<volume>24</volume>
<issue>188</issue>
</element-citation>
</ref>
<ref id="R12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Le</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Andreadakis</surname>
<given-names>Zacharias</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>Arun</given-names>
</name>
<name>
<surname>Román</surname>
<given-names>Raúl Gómez</given-names>
</name>
<name>
<surname>Stig</surname>
<given-names>Tollefsen</given-names>
</name>
<name>
<surname>MelanieSaville</surname>
</name>
</person-group>
<article-title>The COVID-19 vaccine development landscape</article-title>
<source>Nature Reviews Drug Discovery</source>
<year>2020</year>
<volume>19</volume>
<fpage>305</fpage>
<lpage>306</lpage>
</element-citation>
</ref>
<ref id="R13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>Q</given-names>
</name>
</person-group>
<article-title>Progress and Prospects on VaccineDevelopment against SARS-CoV-2.Vaccines(Basel)</article-title>
<year>2020</year>
<volume>8</volume>
<issue>2</issue>
<fpage>153</fpage>
<pub-id pub-id-type="doi">10.3390/vaccines8020153</pub-id>
</element-citation>
</ref>
<ref id="R14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoffmann</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kleine-Weber</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Schroeder</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cell</surname>
<given-names>NK</given-names>
</name>
</person-group>
<article-title>SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor</article-title>
<source>Cell</source>
<year>2020</year>
<volume>181</volume>
<issue>2</issue>
<fpage>271</fpage>
<lpage>280</lpage>
</element-citation>
</ref>
<ref id="R15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lindenbach</surname>
<given-names>BD</given-names>
</name>
<name>
<surname>Rice</surname>
<given-names>CM</given-names>
</name>
</person-group>
<article-title>Molecular biology of flaviviruses</article-title>
<source>Advances in VirusResearch</source>
<year>2003</year>
<volume>59</volume>
<fpage>23</fpage>
<lpage>61</lpage>
</element-citation>
</ref>
<ref id="R16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Folaranmi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Rubin</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>M</given-names>
</name>
<name>
<surname>MacNeil</surname>
<given-names>JR</given-names>
</name>
</person-group>
<article-title>Use of Serogroup BMeningococcal Vaccines in Persons Aged ≥10 Years at Increased Risk for Serogroup B Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2015</article-title>
<source>MMWR</source>
<year>2015</year>
<volume>64</volume>
<issue>22</issue>
<fpage>608</fpage>
<lpage>612</lpage>
</element-citation>
</ref>
<ref id="R17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Azmi</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Fuaad</surname>
<given-names>AAHA</given-names>
</name>
<name>
<surname>Skwarczynski</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Toth</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Recent progress in adjuvant discovery for peptide based subunit vaccines</article-title>
<source>Human Vaccines and Immunotherapeutics</source>
<year>2014</year>
<volume>10</volume>
<fpage>778</fpage>
<lpage>796</lpage>
</element-citation>
</ref>
<ref id="R18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahmed</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Quadeer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>McKay</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies1</article-title>
<source>Viruses</source>
<year>2020</year>
<volume>12</volume>
<issue>3</issue>
<fpage>254</fpage>
</element-citation>
</ref>
<ref id="R19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weingartl</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Czub</surname>
<given-names>Markus</given-names>
</name>
<name>
<surname>Czub</surname>
<given-names>Stefanie</given-names>
</name>
<name>
<surname>Neufled</surname>
<given-names>James</given-names>
</name>
<name>
<surname>Marszal</surname>
<given-names>Peter</given-names>
</name>
<name>
<surname>Gren</surname>
<given-names>Jason</given-names>
</name>
<etal/>
</person-group>
<article-title>Immunization with Modified Vaccinia Virus Ankara-Based Recombinant Vaccine against Severe Acute Respiratory Syndrome Is Associated with Enhanced Hepatitis in Ferrets</article-title>
<source>J Virol</source>
<year>2004</year>
<volume>78</volume>
<fpage>12672</fpage>
<lpage>12676</lpage>
</element-citation>
</ref>
<ref id="R20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Czub</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Weingartl</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Czub</surname>
<given-names>S</given-names>
</name>
<name>
<surname>He</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets</article-title>
<source>Vaccine</source>
<year>2005</year>
<volume>23</volume>
<issue>17-18</issue>
<fpage>2273</fpage>
<lpage>2279</lpage>
</element-citation>
</ref>
<ref id="R21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanchez-Mazas</surname>
<given-names>Alicia</given-names>
</name>
</person-group>
<article-title>HLA studies in the context of coronavirus outbreaks</article-title>
<source>Swiss Med Wkly</source>
<year>2020</year>
<volume>150</volume>
<fpage>w20248</fpage>
</element-citation>
</ref>
<ref id="R22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bateman</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>UniProt: A worldwide hub of protein knowledge</article-title>
<source>Nucleic Acids Research</source>
<year>2019</year>
<volume>47</volume>
<fpage>D506</fpage>
<lpage>D515</lpage>
</element-citation>
</ref>
<ref id="R23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gasteiger</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Gattiker</surname>
<given-names>Alexandre</given-names>
</name>
<name>
<surname>Hoogland</surname>
<given-names>Christine</given-names>
</name>
<name>
<surname>Ivanyi</surname>
<given-names>Ivan</given-names>
</name>
<name>
<surname>Appel</surname>
<given-names>Ron D</given-names>
</name>
<name>
<surname>Amos</surname>
<given-names>Bairoch</given-names>
</name>
<etal/>
</person-group>
<article-title>ExPASy: The proteomics server for in-depth protein knowledge and analysis</article-title>
<source>Nucleic Acids Research</source>
<year>2003</year>
<volume>31</volume>
<fpage>3784</fpage>
<lpage>3788</lpage>
</element-citation>
</ref>
<ref id="R24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Madeira</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>Young Mi</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>Joon</given-names>
</name>
<name>
<surname>Buso</surname>
<given-names>Nicola</given-names>
</name>
<name>
<surname>Gur</surname>
<given-names>Tamer</given-names>
</name>
<name>
<surname>Nandana</surname>
<given-names>Madhusoodanan</given-names>
</name>
<etal/>
</person-group>
<article-title>The EMBL-EBI search and sequence analysis tools APIs in 2019</article-title>
<source>Nucleic Acids Research</source>
<year>2019</year>
<volume>47</volume>
<fpage>W636</fpage>
<lpage>W641</lpage>
</element-citation>
</ref>
<ref id="R25">
<label>25</label>
<element-citation publication-type="web">
<collab>Peptide Hydrophobicity/Hydrophilicity Analysis Tool</collab>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://www.peptide2.com/N_peptide_hydrophobicity_hydrophilicity.php">https://www.peptide2.com/N_peptide_hydrophobicity_hydrophilicity.php</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R26">
<label>26</label>
<element-citation publication-type="web">
<article-title>Protein Calculator</article-title>
<comment>
<ext-link ext-link-type="uri" xlink:href="http://protcalc.sourceforge.net/">http://protcalc.sourceforge.net/</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R27">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kryshtafovych</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Schwede</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Topf</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Moult</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Critical assessment of methods of protein structure prediction (CASP)—Round XIII</article-title>
<source>Proteins: Structure, Function, and Bioinformatics</source>
<year>2019</year>
<volume>87</volume>
<fpage>1011</fpage>
<lpage>1020</lpage>
</element-citation>
</ref>
<ref id="R28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Waterhouse</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Martino</surname>
<given-names>Bertoni</given-names>
</name>
<name>
<surname>Stefan</surname>
<given-names>Bienert</given-names>
</name>
<name>
<surname>Gabriel</surname>
<given-names>Studer</given-names>
</name>
<name>
<surname>Gerardo</surname>
<given-names>Tauriello</given-names>
</name>
<name>
<surname>Rafal</surname>
<given-names>Gumienny</given-names>
</name>
<etal/>
</person-group>
<article-title>SWISS-MODEL: Homology modelling of protein structures and complexes</article-title>
<source>Nucleic Acids Research</source>
<year>2018</year>
<volume>46</volume>
<fpage>W296</fpage>
<lpage>W303</lpage>
</element-citation>
</ref>
<ref id="R29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Chengxin</given-names>
</name>
<name>
<surname>Wuyun</surname>
<given-names>Qiqige</given-names>
</name>
<name>
<surname>Pearce</surname>
<given-names>Robin</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Yang</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Yang</given-names>
</name>
<etal/>
</person-group>
<article-title>LOMETS2: improved meta-threading server for fold-recognition and structure-based function annotation for distant-homology proteins</article-title>
<source>Nucleic Acids Research</source>
<year>2019</year>
<volume>47</volume>
<fpage>W429</fpage>
<lpage>W436</lpage>
</element-citation>
</ref>
<ref id="R30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McGuffin</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Atkins</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Salehe</surname>
<given-names>BR</given-names>
</name>
<name>
<surname>Roche</surname>
<given-names>DB</given-names>
</name>
</person-group>
<article-title>IntFOLD: An integrated server for modelling protein structures and functions from amino acid sequences</article-title>
<source>Nucleic Acids Research</source>
<year>2015</year>
<volume>43</volume>
<fpage>W169</fpage>
<lpage>W173</lpage>
</element-citation>
</ref>
<ref id="R31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>Renxiang</given-names>
</name>
<name>
<surname>Roy</surname>
<given-names>Ambrish</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Dong</given-names>
</name>
<name>
<surname>Poisson</surname>
<given-names>Jonathan</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Yang</given-names>
</name>
<etal/>
</person-group>
<article-title>The I-TASSER Suite: protein structure and function prediction</article-title>
<source>Nature Methods</source>
<year>2015</year>
<volume>12</volume>
<fpage>7</fpage>
<lpage>8</lpage>
</element-citation>
</ref>
<ref id="R32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Haicang</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>Wei-Mou</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Dong</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Jianwei</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Bing</given-names>
</name>
<etal/>
</person-group>
<article-title>FALCON: A high-throughput protein structure prediction server based on remote homologue recognition</article-title>
<source>Bioinformatics</source>
<year>2016</year>
<volume>32</volume>
<fpage>462</fpage>
<lpage>464</lpage>
</element-citation>
</ref>
<ref id="R33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Afgan</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>Dannon</given-names>
</name>
<name>
<surname>Batut</surname>
<given-names>Bérénice</given-names>
</name>
<name>
<surname>Marius van den</surname>
<given-names>Beek</given-names>
</name>
<name>
<surname>Bouvier</surname>
<given-names>Dave</given-names>
</name>
<name>
<surname>Cech</surname>
<given-names>Martin</given-names>
</name>
<etal/>
</person-group>
<article-title>The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2018 update</article-title>
<source>Nucleic Acids Research</source>
<year>2018</year>
<volume>46</volume>
<fpage>W537</fpage>
<lpage>W544</lpage>
</element-citation>
</ref>
<ref id="R34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Källberg</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Haipeng</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Sheng</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>Jian</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Zhiyong</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Hui</given-names>
</name>
<etal/>
</person-group>
<article-title>Template-based protein structure modeling using the RaptorX web server</article-title>
<source>Nature Protocols</source>
<year>2012</year>
<volume>7</volume>
<fpage>1511</fpage>
<lpage>1522</lpage>
</element-citation>
</ref>
<ref id="R35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Ab initio protein structure assembly using continuous structure fragments and optimized knowledge-based force field</article-title>
<source>Proteins: Structure, Function and Bioinformatics</source>
<year>2012</year>
<volume>80</volume>
<fpage>1715</fpage>
<lpage>1735</lpage>
</element-citation>
</ref>
<ref id="R36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heo</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Seok</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>GalaxyRefine: Protein structure refinement driven by side-chain repacking</article-title>
<source>Nucleic acids research</source>
<year>2013</year>
<volume>41</volume>
<fpage>W384</fpage>
<lpage>W388</lpage>
</element-citation>
</ref>
<ref id="R37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ramachandran</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kota</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Dokholyan</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Automated minimization of steric clashes in protein structures</article-title>
<source>Proteins: Structure, Function and Bioinformatics</source>
<year>2011</year>
<volume>79</volume>
<fpage>261</fpage>
<lpage>270</lpage>
</element-citation>
</ref>
<ref id="R38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laskowski</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>MacArthur</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Thornton</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>PROCHECK: a program to check the stereochemical quality of protein structures</article-title>
<source>Journal of Applied Crystallography</source>
<year>1993</year>
<volume>26</volume>
<fpage>283</fpage>
<lpage>291</lpage>
</element-citation>
</ref>
<ref id="R39">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eisenberg</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bowie</surname>
<given-names>JU</given-names>
</name>
</person-group>
<article-title>VERIFY3D: Assessment of protein models with three dimensional profiles</article-title>
<source>Methods in Enzymology</source>
<year>1997</year>
<volume>277</volume>
<fpage>396</fpage>
<lpage>404</lpage>
</element-citation>
</ref>
<ref id="R40">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Colovos</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Yeates</surname>
<given-names>TO</given-names>
</name>
</person-group>
<article-title>Verification of protein structures: patterns of nonbonded atomic interactions</article-title>
<source>Protein science : a publication of the Protein Society</source>
<year>1993</year>
<volume>2</volume>
<issue>9</issue>
<fpage>1511</fpage>
<lpage>1519</lpage>
</element-citation>
</ref>
<ref id="R41">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pontius</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Richelle</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wodak</surname>
<given-names>SJ</given-names>
</name>
</person-group>
<article-title>Deviations from standard atomic volumes as a quality measure for protein crystal structures</article-title>
<source>J Mol Bio</source>
<year>1996</year>
<volume>264</volume>
<issue>1</issue>
<fpage>121</fpage>
<lpage>136</lpage>
</element-citation>
</ref>
<ref id="R42">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pucci</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Kwasigroch</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Rooman</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>SCooP: an accurate and fast predictor of protein stability curves as a function of temperature</article-title>
<source>Bioinformatics (Oxford, England)</source>
<year>2017</year>
<volume>33</volume>
<fpage>3415</fpage>
<lpage>3422</lpage>
</element-citation>
</ref>
<ref id="R43">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scott</surname>
<given-names>WRP</given-names>
</name>
<etal/>
</person-group>
<article-title>The GROMOS biomolecular simulation program package</article-title>
<source>The Journal of Physical Chemistry A</source>
<year>1999</year>
<volume>103</volume>
<fpage>3596</fpage>
<lpage>3607</lpage>
</element-citation>
</ref>
<ref id="R44">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Doytchinova</surname>
<given-names>IA</given-names>
</name>
<name>
<surname>Flower</surname>
<given-names>DR</given-names>
</name>
</person-group>
<article-title>VaxiJen: A server for prediction of protective antigens, tumour antigens and subunit vaccines</article-title>
<source>BMC Bioinformatics</source>
<year>2007</year>
<volume>8</volume>
<fpage>4</fpage>
</element-citation>
</ref>
<ref id="R45">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gonzalez-Galarza</surname>
<given-names>FF</given-names>
</name>
<name>
<surname>McCabe</surname>
<given-names>Antony</given-names>
</name>
<name>
<surname>Melo Dos Santos</surname>
<given-names>Eduardo J</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>James</given-names>
</name>
<name>
<surname>Takeshita</surname>
<given-names>Louise</given-names>
</name>
<name>
<surname>Ortega-Rivera</surname>
<given-names>Nestor D</given-names>
</name>
<etal/>
</person-group>
<article-title>Allele frequency net database (AFND) 2020 update: Gold-standard data classification, open access genotype data and new query tools</article-title>
<source>Nucleic Acids Research</source>
<year>2020</year>
<volume>48</volume>
<fpage>D783</fpage>
<lpage>D788</lpage>
</element-citation>
</ref>
<ref id="R46">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reynisson</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Alvarez</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Paul</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Nielsen</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>NetMHCpan-4.1 and NetMHCIIpan-4.0 improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data</article-title>
<source>Nucleic acids research</source>
<year>2020</year>
<volume>48</volume>
<fpage>W449</fpage>
<lpage>W454</lpage>
</element-citation>
</ref>
<ref id="R47">
<label>47</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vita</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Mahajan</surname>
<given-names>Swapnil</given-names>
</name>
<name>
<surname>Overton</surname>
<given-names>James A</given-names>
</name>
<name>
<surname>Dhanda</surname>
<given-names>Sandeep Kumar</given-names>
</name>
<name>
<surname>Martini</surname>
<given-names>Sheridan</given-names>
</name>
<name>
<surname>Cantrell</surname>
<given-names>Jason R</given-names>
</name>
<etal/>
</person-group>
<article-title>The Immune Epitope Database (IEDB): 2018 update</article-title>
<source>Nucleic Acids Research</source>
<year>2019</year>
<volume>47</volume>
<fpage>D339</fpage>
<lpage>D343</lpage>
</element-citation>
</ref>
<ref id="R48">
<label>48</label>
<element-citation publication-type="web">
<article-title>Bioinformatics tool for allergenicity prediction</article-title>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://www.ddgpharmfac.net/AllerTOP/index.html">https://www.ddgpharmfac.net/AllerTOP/index.html</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R49">
<label>49</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gupta</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kapoor</surname>
<given-names>Pallavi</given-names>
</name>
<name>
<surname>Chaudhary</surname>
<given-names>Kumardeep</given-names>
</name>
<name>
<surname>Gautam</surname>
<given-names>Ankur</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>Rahul</given-names>
</name>
<name>
<surname>Raghava</surname>
<given-names>Gajendra PS</given-names>
</name>
<etal/>
</person-group>
<article-title>In Silico Approach for Predicting Toxicity of Peptides and Proteins</article-title>
<source>PLoS ONE</source>
<year>2013</year>
<volume>8</volume>
<fpage>e73957</fpage>
</element-citation>
</ref>
<ref id="R50">
<label>50</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lamiable</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Thévenet</surname>
<given-names>Pierre</given-names>
</name>
<name>
<surname>Rey</surname>
<given-names>Julien</given-names>
</name>
<name>
<surname>Vavrusa</surname>
<given-names>Marek</given-names>
</name>
<name>
<surname>Derreumaux</surname>
<given-names>Philippe</given-names>
</name>
<etal/>
</person-group>
<article-title>PEP-FOLD3: faster de novo structure prediction for linear peptides in solution and in complex</article-title>
<source>Nucleic acids research</source>
<year>2016</year>
<volume>44</volume>
<fpage>W449</fpage>
<lpage>W454</lpage>
</element-citation>
</ref>
<ref id="R51">
<label>51</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pettersen</surname>
<given-names>EF</given-names>
</name>
<name>
<surname>Goddard</surname>
<given-names>Thomas D</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Conrad C</given-names>
</name>
<name>
<surname>Couch</surname>
<given-names>Gregory S</given-names>
</name>
<name>
<surname>Greenblatt</surname>
<given-names>Daniel M</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>Elaine C</given-names>
</name>
<etal/>
</person-group>
<article-title>UCSF Chimera - A visualization system for exploratory research and analysis</article-title>
<source>Journal of Computational Chemistry</source>
<year>2004</year>
<volume>25</volume>
<fpage>1605</fpage>
<lpage>1612</lpage>
</element-citation>
</ref>
<ref id="R52">
<label>52</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schneidman-Duhovny</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Inbar</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wolfson</surname>
<given-names>HJ</given-names>
</name>
</person-group>
<article-title>PatchDock and SymmDock: Servers for rigid and symmetric docking</article-title>
<source>Nucleic Acids Research</source>
<year>2005</year>
<volume>33</volume>
<fpage>W363</fpage>
</element-citation>
</ref>
<ref id="R53">
<label>53</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mashiach</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Schneidman-Duhovny</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Andrusier</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Wolfson</surname>
<given-names>HJ</given-names>
</name>
</person-group>
<article-title>FireDock: a web server for fast interaction refinement in molecular docking</article-title>
<source>Nucleic acids research</source>
<year>2008</year>
<volume>36</volume>
<fpage>W229</fpage>
</element-citation>
</ref>
<ref id="R54">
<label>54</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Celniker</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Nimrod</surname>
<given-names>Guy</given-names>
</name>
<name>
<surname>Haim</surname>
<given-names>Ashkenazy</given-names>
</name>
<name>
<surname>Fabian</surname>
<given-names>Glaser</given-names>
</name>
<name>
<surname>Eric</surname>
<given-names>Martz</given-names>
</name>
<name>
<surname>Itay</surname>
<given-names>Mayrose</given-names>
</name>
<etal/>
</person-group>
<article-title>ConSurf: Using evolutionary data to raise testable hypotheses about protein function</article-title>
<source>Israel Journal of Chemistry</source>
<year>2013</year>
<volume>53</volume>
<fpage>199</fpage>
<lpage>206</lpage>
<pub-id pub-id-type="doi">10.1002/ijch.201200096</pub-id>
</element-citation>
</ref>
<ref id="R55">
<label>55</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Glaser</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Tal</surname>
<given-names>Pupko</given-names>
</name>
<name>
<surname>Inbal</surname>
<given-names>Paz</given-names>
</name>
<name>
<surname>Bell</surname>
<given-names>Rachel E</given-names>
</name>
<name>
<surname>Dalit</surname>
<given-names>Bechor-Shental</given-names>
</name>
<name>
<surname>Eric</surname>
<given-names>Martz</given-names>
</name>
<etal/>
</person-group>
<article-title>ConSurf: Identification of functional regions in proteins by surface-mapping of phylogenetic information</article-title>
<source>Bioinformatics</source>
<year>2003</year>
<volume>19</volume>
<issue>1</issue>
<fpage>163</fpage>
<lpage>4</lpage>
<pub-id pub-id-type="doi">10.1093/bioinformatics/19.1.163</pub-id>
</element-citation>
</ref>
<ref id="R56">
<label>56</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bui</surname>
<given-names>HH</given-names>
</name>
<name>
<surname>Sidney</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Sette</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Development of an epitope conservancy analysis tool to facilitate the design of epitope-based diagnostics and vaccines</article-title>
<source>BMC Bioinformatics</source>
<year>2007</year>
<volume>8</volume>
<fpage>361</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2105-8-361</pub-id>
</element-citation>
</ref>
<ref id="R57">
<label>57</label>
<element-citation publication-type="web">
<article-title>Coronavirus Disease (COVID-19) Situation Reports</article-title>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/diseases/novelcoronavirus-2019/situation-reports">https://www.who.int/emergencies/diseases/novelcoronavirus-2019/situation-reports</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R58">
<label>58</label>
<element-citation publication-type="web">
<article-title>Milken Institute Covid-19vaccinetracker.org</article-title>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://www.covid-19vaccinetracker.org/">https://www.covid-19vaccinetracker.org/</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R59">
<label>59</label>
<element-citation publication-type="web">
<article-title>MHCcluster Server</article-title>
<comment>
<ext-link ext-link-type="uri" xlink:href="http://www.cbs.dtu.dk/services/MHCcluster/">http://www.cbs.dtu.dk/services/MHCcluster/</ext-link>
</comment>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p>Schematic representation of the workflow:</p>
</caption>
<graphic xlink:href="EMS98566-f001"/>
</fig>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<p>The predicted structures of the top 4 most stable proteins with their solvent accessibility surface diagrams. The predicted models were visualized using Biovia Discovery Studio Visualizer. (A) Q7TFA0 (B) Q7TLC7 (C) P0DTD3 and (D) M4SVF1.</p>
</caption>
<graphic xlink:href="EMS98566-f002"/>
</fig>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption>
<p>Phylogenetic tree of the 5 HLA Subtypes analyzed in this study generated using MHC Cluster 2.0 Server<sup>60</sup>
</p>
</caption>
<graphic xlink:href="EMS98566-f003"/>
</fig>
<fig id="F4" position="float">
<label>Figure 4</label>
<caption>
<p>Conservation of T-Cell Epitopes in SARS-CoV-2. The position of conserved epitopes in the protein sequence. (A) P0DTC6 (B) P0DTC8 (C) P0DTD8. According to the neural network algorithm, The orange coloured ‘e’ represents exposed residues, the green colored ‘b’ represents buried residues, the red colored ’f’ represents functional residues (highly conserved and exposed) and the dark blue colored ‘s’ represents structural residues (highly conserved and buried). The conservation scale represents the status of conservation from variable, average to conserved.</p>
</caption>
<graphic xlink:href="EMS98566-f004"/>
</fig>
<fig id="F5" position="float">
<label>Figure 5</label>
<caption>
<p>Graphical presentation of the predicted interactions between MHC class 1 binding T cell epitopes from the modelled proteins and HLA alleles. (A) Epitope: LAPHHVVAV bound to HLA-B*08:01 with a global binding energy of -68.71. (B) Epitope: AVGEILLLEW bound to HLA-B*58:01 with a global binding energy of -52.01. (C) Epitope: KVSIWNLDY bound to HLA-A*11:01 with a global binding energy of -43.03. (D) Epitope: IIFWFSLEL bound to HLA-A*11:01 with a global binding energy of -42.77.</p>
</caption>
<graphic xlink:href="EMS98566-f005"/>
</fig>
<table-wrap id="T1" position="float" orientation="portrait">
<label>Table 1</label>
<caption>
<title>Analysis of Identified Protein Sequences</title>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">Uniprot ID</th>
<th align="left" valign="top">Length</th>
<th align="left" valign="top">Mass</th>
<th align="left" valign="top">IpH</th>
<th align="left" valign="top">Arginine</th>
<th align="left" valign="top">Cystine</th>
<th align="left" valign="top">Histidine</th>
<th align="left" valign="top">Lysine</th>
<th align="left" valign="top">Non Polar Amino</th>
<th align="left" valign="top">Polar Amino</th>
<th align="left" valign="top">Hydrophobicity Index</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">Q7TFA0</td>
<td align="left" valign="top">39</td>
<td align="left" valign="top">4.33</td>
<td align="left" valign="top">8.30</td>
<td align="left" valign="top">2.60%</td>
<td align="left" valign="top">15.40%</td>
<td align="left" valign="top">5.10%</td>
<td align="left" valign="top">7.70%</td>
<td align="left" valign="top">58.974</td>
<td align="left" valign="top">41.026</td>
<td align="left" valign="top">43.59%</td>
</tr>
<tr>
<td align="left" valign="top">P0DTD8</td>
<td align="left" valign="top">43</td>
<td align="left" valign="top">5.18</td>
<td align="left" valign="top">4.17</td>
<td align="left" valign="top">0.00%</td>
<td align="left" valign="top">4.70%</td>
<td align="left" valign="top">4.70%</td>
<td align="left" valign="top">0.00%</td>
<td align="left" valign="top">72.093</td>
<td align="left" valign="top">27.907</td>
<td align="left" valign="top">65.12%</td>
</tr>
<tr>
<td align="left" valign="top">P0DTC6</td>
<td align="left" valign="top">61</td>
<td align="left" valign="top">7.27</td>
<td align="left" valign="top">4.60</td>
<td align="left" valign="top">1.60%</td>
<td align="left" valign="top">0.00%</td>
<td align="left" valign="top">1.60%</td>
<td align="left" valign="top">6.60%</td>
<td align="left" valign="top">52.459</td>
<td align="left" valign="top">47.541</td>
<td align="left" valign="top">49.18%</td>
</tr>
<tr>
<td align="left" valign="top">Q7TLC7</td>
<td align="left" valign="top">70</td>
<td align="left" valign="top">7.85</td>
<td align="left" valign="top">6.25</td>
<td align="left" valign="top">2.90%</td>
<td align="left" valign="top">5.70%</td>
<td align="left" valign="top">4.30%</td>
<td align="left" valign="top">5.70%</td>
<td align="left" valign="top">64.286</td>
<td align="left" valign="top">35.714</td>
<td align="left" valign="top">54.29%</td>
</tr>
<tr>
<td align="left" valign="top">P0DTD3</td>
<td align="left" valign="top">73</td>
<td align="left" valign="top">8.05</td>
<td align="left" valign="top">5.79</td>
<td align="left" valign="top">0.00%</td>
<td align="left" valign="top">6.80%</td>
<td align="left" valign="top">4.10%</td>
<td align="left" valign="top">5.50%</td>
<td align="left" valign="top">64.384</td>
<td align="left" valign="top">35.616</td>
<td align="left" valign="top">53.42%</td>
</tr>
<tr>
<td align="left" valign="top">P0DTC8</td>
<td align="left" valign="top">121</td>
<td align="left" valign="top">13.83</td>
<td align="left" valign="top">5.42</td>
<td align="left" valign="top">3.30%</td>
<td align="left" valign="top">5.80%</td>
<td align="left" valign="top">3.30%</td>
<td align="left" valign="top">4.10%</td>
<td align="left" valign="top">60.331</td>
<td align="left" valign="top">39.669</td>
<td align="left" valign="top">44.63%</td>
</tr>
<tr>
<td align="left" valign="top">M4SVF1</td>
<td align="left" valign="top">224</td>
<td align="left" valign="top">25.25</td>
<td align="left" valign="top">8.48</td>
<td align="left" valign="top">6.20%</td>
<td align="left" valign="top">3.60%</td>
<td align="left" valign="top">3.10%</td>
<td align="left" valign="top">1.30%</td>
<td align="left" valign="top">36.161</td>
<td align="left" valign="top">63.839</td>
<td align="left" valign="top">36.16%</td>
</tr>
<tr>
<td align="left" valign="top">A0A6H2LBE3</td>
<td align="left" valign="top">275</td>
<td align="left" valign="top">31.15</td>
<td align="left" valign="top">5.66</td>
<td align="left" valign="top">2.20%</td>
<td align="left" valign="top">2.50%</td>
<td align="left" valign="top">3.30%</td>
<td align="left" valign="top">4.00%</td>
<td align="left" valign="top">59.273</td>
<td align="left" valign="top">40.727</td>
<td align="left" valign="top">45.45%</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="T2" position="float" orientation="portrait">
<label>Table 2</label>
<caption>
<title>Stability Analysis of the predicted 3D structures.</title>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">UniProt ID</th>
<th align="left" valign="top">ERRAT Values</th>
<th align="left" valign="top">GROMOS96 Force field values</th>
<th align="left" valign="top">Gr kcal/mol</th>
<th align="left" valign="top">RC Aanalysis</th>
<th align="left" valign="top">Tm C</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">Q7TFA0</td>
<td align="left" valign="top">94.1176</td>
<td align="left" valign="top">-549.952</td>
<td align="left" valign="top">-28.7</td>
<td align="left" valign="top">100.00%</td>
<td align="left" valign="top">114.3</td>
</tr>
<tr>
<td align="left" valign="top">Q7TLC7</td>
<td align="left" valign="top">93.5484</td>
<td align="left" valign="top">-2728.715</td>
<td align="left" valign="top">-9.6</td>
<td align="left" valign="top">89.30%</td>
<td align="left" valign="top">65</td>
</tr>
<tr>
<td align="left" valign="top">P0DTD3</td>
<td align="left" valign="top">84.9057</td>
<td align="left" valign="top">-1550.547</td>
<td align="left" valign="top">-11.3</td>
<td align="left" valign="top">100.00%</td>
<td align="left" valign="top">69.4</td>
</tr>
<tr>
<td align="left" valign="top">M4SVF1</td>
<td align="left" valign="top">84.7222</td>
<td align="left" valign="top">-6842.415</td>
<td align="left" valign="top">-5.7</td>
<td align="left" valign="top">92.20%</td>
<td align="left" valign="top">70.9</td>
</tr>
<tr>
<td align="left" valign="top">P0DTC6</td>
<td align="left" valign="top">83.0189</td>
<td align="left" valign="top">-1689.699</td>
<td align="left" valign="top">-13.7</td>
<td align="left" valign="top">94.80%</td>
<td align="left" valign="top">85.5</td>
</tr>
<tr>
<td align="left" valign="top">P0DTD8</td>
<td align="left" valign="top">80.6452</td>
<td align="left" valign="top">-435.783</td>
<td align="left" valign="top">-20.7</td>
<td align="left" valign="top">100.00%</td>
<td align="left" valign="top">101.7</td>
</tr>
<tr>
<td align="left" valign="top">P0DTC8</td>
<td align="left" valign="top">71.4286</td>
<td align="left" valign="top">-1854.744</td>
<td align="left" valign="top">-4.3</td>
<td align="left" valign="top">98.10%</td>
<td align="left" valign="top">84.3</td>
</tr>
<tr>
<td align="left" valign="top">A0A6H2LBE3</td>
<td align="left" valign="top">64.557</td>
<td align="left" valign="top">-5955.949</td>
<td align="left" valign="top">-2.2</td>
<td align="left" valign="top">95.20%</td>
<td align="left" valign="top">73.6</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="T3" position="float" orientation="portrait">
<label>Table 3</label>
<caption>
<title>Immunogenicity analysis of predicted MHC Class 1 epitopes.</title>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">Protein</th>
<th align="left" valign="top">Epitope Sequence</th>
<th align="left" valign="top">HLA Subtype</th>
<th align="left" valign="top">Antigenicity</th>
<th align="left" valign="top">Immunogenicity</th>
<th align="left" valign="top">Allergenicity</th>
<th align="left" valign="top">Toxicity</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">P0DTC6</td>
<td align="left" valign="top">HLVDFQVTI</td>
<td align="left" valign="top">HLA-A*02:01</td>
<td align="left" valign="top">1.4119</td>
<td align="left" valign="top">0.0982</td>
<td align="left" valign="top">non allergen</td>
<td align="left" valign="top">non toxin</td>
</tr>
<tr>
<td align="left" valign="top">P0DTC8</td>
<td align="left" valign="top">RKSAPLIEL</td>
<td align="left" valign="top">HLA-B*27:05</td>
<td align="left" valign="top">1.1591</td>
<td align="left" valign="top">0.13525</td>
<td align="left" valign="top">non allergen</td>
<td align="left" valign="top">non toxin</td>
</tr>
<tr>
<td align="left" valign="top">P0DTD8</td>
<td align="left" valign="top">YLCFLAFLL</td>
<td align="left" valign="top">HLA-A*02:01</td>
<td align="left" valign="top">0.9143</td>
<td align="left" valign="top">0.21865</td>
<td align="left" valign="top">non allergen</td>
<td align="left" valign="top">non toxin</td>
</tr>
<tr>
<td align="left" valign="top">Q7TLC7</td>
<td align="left" valign="top">LAPHHVVAV</td>
<td align="left" valign="top">HLA-B*08:01</td>
<td align="left" valign="top">0.877</td>
<td align="left" valign="top">0.15701</td>
<td align="left" valign="top">non allergen</td>
<td align="left" valign="top">non toxin</td>
</tr>
<tr>
<td align="left" valign="top">P0DTD8</td>
<td align="left" valign="top">IIFWFSLEL</td>
<td align="left" valign="top">HLA-A*11:01</td>
<td align="left" valign="top">0.8291</td>
<td align="left" valign="top">0.2683</td>
<td align="left" valign="top">non allergen</td>
<td align="left" valign="top">non toxin</td>
</tr>
<tr>
<td align="left" valign="top">P0DTC6</td>
<td align="left" valign="top">KVSIWNLDY</td>
<td align="left" valign="top">HLA-A*11:01</td>
<td align="left" valign="top">0.8195</td>
<td align="left" valign="top">0.29343</td>
<td align="left" valign="top">non allergen</td>
<td align="left" valign="top">non toxin</td>
</tr>
<tr>
<td align="left" valign="top">P0DTD8</td>
<td align="left" valign="top">LLFLVLIML</td>
<td align="left" valign="top">HLA-A*02:01</td>
<td align="left" valign="top">0.7047</td>
<td align="left" valign="top">0.06632</td>
<td align="left" valign="top">non allergen</td>
<td align="left" valign="top">non toxin</td>
</tr>
<tr>
<td align="left" valign="top">Q7TLC7</td>
<td align="left" valign="top">AVGEILLLEW</td>
<td align="left" valign="top">HLA-B*58:01</td>
<td align="left" valign="top">0.53</td>
<td align="left" valign="top">0.26925</td>
<td align="left" valign="top">non allergen</td>
<td align="left" valign="top">non toxin</td>
</tr>
<tr>
<td align="left" valign="top">P0DTD8</td>
<td align="left" valign="top">FLAFLLFLV</td>
<td align="left" valign="top">HLA-A*02:01</td>
<td align="left" valign="top">0.4956</td>
<td align="left" valign="top">0.20158</td>
<td align="left" valign="top">non allergen</td>
<td align="left" valign="top">non toxin</td>
</tr>
<tr>
<td align="left" valign="top">P0DTD8</td>
<td align="left" valign="top">MLIIFWFSL</td>
<td align="left" valign="top">HLA-A*02:01</td>
<td align="left" valign="top">0.4022</td>
<td align="left" valign="top">0.50177</td>
<td align="left" valign="top">non allergen</td>
<td align="left" valign="top">non toxin</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="T4" position="float" orientation="portrait">
<label>Table 4</label>
<caption>
<title>Global binding energies of the predicted epitope sequences</title>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">Protein</th>
<th align="left" valign="top">Epitope Sequence</th>
<th align="left" valign="top">Binding HLA Subtypes</th>
<th align="left" valign="top">Global binding energy</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">Q7TLC7</td>
<td align="left" valign="top">LAPHHVVAV</td>
<td align="left" valign="top">HLA-B*08:01</td>
<td align="left" valign="top">-68.71</td>
</tr>
<tr>
<td align="left" valign="top">Q7TLC7</td>
<td align="left" valign="top">AVGEILLLEW</td>
<td align="left" valign="top">HLA-B*58:01</td>
<td align="left" valign="top">-52.01</td>
</tr>
<tr>
<td align="left" valign="top">P0DTC6</td>
<td align="left" valign="top">KVSIWNLDY</td>
<td align="left" valign="top">HLA-A*11:01</td>
<td align="left" valign="top">-43.03</td>
</tr>
<tr>
<td align="left" valign="top">P0DTD8</td>
<td align="left" valign="top">IIFWFSLEL</td>
<td align="left" valign="top">HLA-A*11:01</td>
<td align="left" valign="top">-42.77</td>
</tr>
<tr>
<td align="left" valign="top">P0DTC8</td>
<td align="left" valign="top">RKSAPLIEL</td>
<td align="left" valign="top">HLA-B*27:05</td>
<td align="left" valign="top">-42.17</td>
</tr>
<tr>
<td align="left" valign="top">P0DTD8</td>
<td align="left" valign="top">FLAFLLFLV</td>
<td align="left" valign="top">HLA-A*02:01</td>
<td align="left" valign="top">-37.72</td>
</tr>
<tr>
<td align="left" valign="top">P0DTC6</td>
<td align="left" valign="top">HLVDFQVTI</td>
<td align="left" valign="top">HLA-A*02:01</td>
<td align="left" valign="top">-37.58</td>
</tr>
<tr>
<td align="left" valign="top">P0DTD8</td>
<td align="left" valign="top">YLCFLAFLL</td>
<td align="left" valign="top">HLA-A*02:01</td>
<td align="left" valign="top">-28.75</td>
</tr>
<tr>
<td align="left" valign="top">P0DTD8</td>
<td align="left" valign="top">LLFLVLIML</td>
<td align="left" valign="top">HLA-A*02:01</td>
<td align="left" valign="top">-19.33</td>
</tr>
<tr>
<td align="left" valign="top">P0DTD8</td>
<td align="left" valign="top">MLIIFWFSL</td>
<td align="left" valign="top">HLA-A*02:01</td>
<td align="left" valign="top">-11.19</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="T5" position="float" orientation="portrait">
<label>Table 5</label>
<caption>
<title>PDB ID of selected HLA Subtypes</title>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">HLA Subtype</th>
<th align="left" valign="top">PDB ID</th>
<th align="left" valign="top">Name</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">HLA-A*02:01</td>
<td align="left" valign="top">4U6X</td>
<td align="left" valign="top">Crystal Structure of HLA-A*0201 in complex with ALQDA, a 15 mer self-peptide</td>
</tr>
<tr>
<td align="left" valign="top">HLA-A*11:01</td>
<td align="left" valign="top">5WJN</td>
<td align="left" valign="top">Crystal Structure of HLA-A*11:01-GTS3</td>
</tr>
<tr>
<td align="left" valign="top">HLA-B*08:01</td>
<td align="left" valign="top">4QRQ</td>
<td align="left" valign="top">Crystal Structure of HLA B*0801 in complex with HSKKKCDEL</td>
</tr>
<tr>
<td align="left" valign="top">HLA-B*27:05</td>
<td align="left" valign="top">2BSS</td>
<td align="left" valign="top">Crystal structures and KIR3DL1 recognition of three immunodominant viral peptides complexed to HLA-B2705</td>
</tr>
<tr>
<td align="left" valign="top">HLA-B*58:01</td>
<td align="left" valign="top">5INC</td>
<td align="left" valign="top">Crystal structure of HLA-B5801, a protective HLA allele for HIV-1 infection</td>
</tr>
</tbody>
</table>
</table-wrap>
</floats-group>
</article>
